BrightOwl Loader Loading


In brief:

  • Passionate scientist with a strong background in pre-clinical translational research & entrepreneurship.
  • Pro-active problem-solver with a critical mindset and eye for detail who creates value.
  • Accessible, to-the-point mentor who leads by example, collaboration and communication.
  • Seasoned writer and presenter with a strong global academic and corporate network.

Bio: Kevin Hollevoet has a degree in Bioengineering (2008, Ghent University, Belgium), a PhD in Medical Sciences (2011, Ghent University), and a postgraduate in Innovation and Entrepreneurship (2017, University of Leuven, Belgium). During his PhD, he managed a Belgian multi-center clinical trial that provided lasting insights on the application of several blood protein markers in the clinical management of mesothelioma. In 2011, Dr. Hollevoet joined the NCI (Bethesda, MD) for a two-year postdoc on immunotoxins (antibody-toxin conjugates). His pre-clinical findings on anti-mesothelin immunotoxins in pancreatic cancer contributed to initiating clinical trials. In 2013, Dr. Hollevoet joined the University of Leuven (KU Leuven), where he currently heads the Antibody Gene Transfer Program at the Laboratory for Therapeutic and Diagnostic Antibodies. This young research branch is dedicated to advancing nucleotide-based antibody therapy in different disease areas, including (immuno-)oncology, infectious diseases and CNS. Dr. Hollevoet is also spearheading an associated spinoff route and acts as Associate Editor for the Journal of Translational Medicine.


Current Experience

  • Associate Editor
    Since April 2017
    Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.

  • Group Leader - Antibody Gene Transfer Program
    Since June 2016
    Built and currently head a pre-clinical program dedicated to gene-based antibody therapy in (immune-)oncology, infectious diseases and CNS (team of 3 FTE), while maturing a spinoff route. Hands-on experience in molecular biology and in vitro & in vivo PK/PD models (mice, hamster and sheep), global academic and corporate network. Lab Director: Prof. Paul Declerck. Supported by an IWT Spinoff Innovation Postdoc Mandate.

Past Experience

  • Postdoctoral Researcher - Antibody Gene Transfer Program
    October 2013 --- May 2016
    Developing an antibody gene-transfer platform for the in vivo production of therapeutic mAbs. Antibody gene transfer is at crossroads between mAb and gene therapy. Following delivery of the DNA that encodes a recombinant mAb of choice, this approach seeks to turn the site of delivery (muscle, tumor, skin) into a ‘bioreactor’, inducing prolonged mAb expression and secretion into circulation. By lowering the cost of goods and frequency of administration, this DNA-based approach represents an innovative alternative to the conventional production and delivery of mAb.

  • Wetenschappelijk medewerker
    August 2011 --- September 2013
    Gained hands-on experience in molecular biology, immunology/immunotherapy, in vitro and in vivo tumor research and drug discovery/development. Specific focus on immunotoxins, mechanisms of resistance, apoptotic pathways in pancreatic cancer and biomarkers. Findings supported clinical trials. Lab Director: Dr. Ira Pastan.

  • PhD Fellow in Medical Sciences
    September 2008 --- June 2011
    Subject: The role of blood protein biomarkers in the management of malignant pleural mesothelioma Evaluated the use of presumed blood protein biomarkers in the management of mesothelioma (diagnosis, screening, prognosis and monitoring therapy response) by executing/managing a Belgian multicenter study (600+ participants) and establishing international collaborations. Specific focus on the effect of patient characteristics on biomarker levels.

  • Master student
    August 2007 --- June 2008
    Study of the expression and methylation status of genes and microRNAs in neuroblastoma


Self Assessment :
ApproachabilityCollaborationCommunicativeCreative thinkingCuriosityOrganizationProactivityProblem solvingSelf-confidenceSelf-disciplineStrategic thinking


Self Assessment :
R&D Scientific writing Animal models Biostatistics NegotiationAntibodiesAssay developmentBiological Drug DevelopmentCancer ResearchCell CultureBiomedical SciencesBudget ManagementBusiness DevelopmentDiagnosticsDrug DeliveryEnzyme-linked immunosorbent assay (ELISA)
LinkedIn Assessment :
ApoptosisBiomarkersCell CultureELISAImmunologyIn Vivomolecular biologyMouse HandlingTranslational MedicineTranslational ResearchPCRqPCRWestern BlottingCellDrug DevelopmentElectroporationCell Based AssaysFACSGrant WritingLaboratory ResearchLiterature ReviewsImmunoprecipitationManuscript EditingMedical PublishingMonoclonal AntibodiesResearch Project ManagementReport WritingReviewProposal WritingStatisticsWriting SkillsXenograftBiotechnologyCell biologyLaboratory SkillsReal-Time Polymerase Chain Reaction (qPCR)Polymerase Chain Reaction (PCR)In Vitroimmunotherapy


  • Postgraduate in Innovation and Entrepreneurship in Engineering from University of Leuven in 2017
  • Bachelor - Master in Bioscience Engineering in Cell and Gene Biotechnology from Ghent University in 2008
  • Master in Biotecnologia from Universidad Politécnica de Valencia in 2007
  • in Latin-Mathematics from Sint-Lodewijkscollege Bruges in 2003

Training and Certification

  • Laboratory Animal Science Certificate Certification


BrightOwl Assessment:
Self Assessment:
Full Proficiency
Elementary Proficiency

Work Preferences

  • Positions I am interested in:
    Business Development Manager Chief Strategy Officer CSO Development Manager Scientific consultant Scientific Officer Team Leader
  • Positions I am NOT interested in:
    Clinical Research Associate (CRA) Medical Science Liaison (MSL) Medical Writer
  • Work From Home:
  • International:

Area / Region

Leuven, Belgium


Driving License
  • Yes